Skip to content

Xencor

US · XNCR #2825 by market cap Listed 1970
24.26 -0.10 -0.41%
Live - 5344 symbols - heartbeat 282s ago · 2026-10-08 07:58
Pre-market 24.26 0.00%
After-hours 24.26 0.00%
Market cap
1.80B
P/B
3.58
EPS
-1.24
Reader sentiment Are you bullish or bearish on XNCR?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 3.60 Expensive vs history 96th percentile
5-year average 2.09 · #327 of 514 in Biotechnology
P/E ratio -11.28 Cheap vs history 16th percentile
5-year average -22.12 · forward -7.48
P/S ratio 17.25 Expensive vs history 94th percentile
5-year average 9.26 · forward 15.39 · #204 of 388 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Xencor (XNCR) 1.80B -11.23 3.58 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value24.11 Economic moatNone UncertaintyVery High

Trading 0.6% above Morningstar's fair value estimate.

Fair value

Xencor Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% premium over our quantitative fair value estimate of $24.11 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The company's lack of profitability weakens our quantitative valuation. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's sales yield of 5.6% lies in the bottom 10% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are expensive.

Conversely, the company's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 6.4, a core component of leverage, sits in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 07:58:21 · For reference only, not investment advice and not tailored to your situation.